Navigation Links
Ironridge Global Partners, LLC Successfully Concludes Equity Financings of ULURU Inc.
Date:8/15/2013

San Francisco (PRWEB) August 15, 2013

Ironridge Global Partners, LLC, an institutional investor making direct equity investments in micro-cap public companies, and its affiliates successfully completed financing transactions with specialty pharmaceutical company ULURU Inc., that were entered into on September 15, 2011, under which Ironridge Global agreed to purchase common and preferred stock. At the election of the company, all outstanding preferred stock was redeemed and all outstanding notes were satisfied in full. Ironridge Global continues to be a common stockholder of the company. ULURU stock closed up today at $0.52 per share.

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex® Aggregate technology and OraDisc™ transmucosal delivery system. For further information about ULURU Inc., please visit its website at http://www.uluruinc.com.

About Ironridge Global Partners®

Ironridge Global Partners, LLC is an institutional investor, making direct equity investments in micro-cap public companies. Its Liability for Equity (LIFE™) program allows public companies to satisfy trade payables, debts and other liabilities in exchange for unregistered common stock utilizing a Section 3(a)(10) fairness hearing. Ironridge Global is the industry leader in this innovative financing structure, which substantially reduces the transactional costs and time necessary to complete a deal. The fund has entered into more than 50 equity financing transactions since 2011, ranging from under a quarter million to over $15 million each. Ironridge Global seeks to be a long-term financial partner, assisting public companies in financing growth and expansion by supplying innovative funding solutions and flexible capital. For more information on Ironridge Global Partners, please visit http://www.IronridgeGlobal.com.

Contact:
Keith Coulston
Ironridge Global Partners, LLC
415-658-9551

Read the full story at http://www.prweb.com/releases/2013/8/prweb11033545.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
2. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
3. Global Cleantech Cluster Association Names New York City Startup Rentricity to Global Top 10 List
4. StemCyte Adds World Class Talent to its North America and Global Operations
5. Sequenom Named to NASDAQ Global Select Market
6. Synthetic Biology: Emerging Global Markets
7. MacroGenics Receives Milestone Payment as Part of Its Global DART™ Alliance with Boehringer Ingelheim
8. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
9. Hemodialysis Machine Industry 2012 Global & China Market Research Report - ReportsnReports
10. MarketsandMarkets: Global Seed Treatment Market worth $3430.3 Million by 2016
11. Accuray Surpasses 600 Installations Globally
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... NetworkNewsWire Editorial Coverage  ... Cancer remains one of ... health care systems, in terms of costs and resources. However, ... the development of innovative and efficient therapies that demonstrate higher ... types of cancer treatments, a growing number of patients receiving ...
(Date:3/22/2017)... , March 22, 2017 Regeneron Pharmaceuticals, Inc. ... Regeneron Genetics Center (RGC), U.K. Biobank and GSK to generate ... U.K. Biobank resource. The initiative will enable researchers to gain ... medicines for a wide range of serious and life threatening ... ...
(Date:3/22/2017)... JERUSALEM , March 22, 2017 ... ( www.oramed.com ), ... of oral drug delivery systems, announced today that ... Officer, will deliver a presentation titled, "Oral Insulin ... upcoming Cambridge Healthtech Institute,s Oligonucleotide and Peptide Therapeutics ...
(Date:3/22/2017)... , March 22, 2017   Boston Biomedical ... cancer therapeutics designed to target cancer stemness pathways, today ... S. Andrews as Chief Executive Officer, effective April ... Chiang J. Li , M.D., FACP, who has ... years ago. Under his leadership, Boston Biomedical has grown ...
Breaking Biology Technology:
(Date:3/16/2017)... CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made in Germany ... ... in one project, multi-biometric solutions provide a crucial contribution against identity fraud. (PRNewsFoto/Dermalog Identification Systems) ... Used combined in one project, multi-biometric solutions provide a crucial ... ...
(Date:3/7/2017)... -- Brandwatch , the leading social intelligence company, today announces ... to uncover insights to support its reporting, help direct future campaigns, ... leading youth charity will be using Brandwatch Analytics social listening and ... understanding of the topics and issues that are a priority for ... "Until ...
(Date:3/2/2017)... Summary This report provides all the information ... partnering interests and activities since 2010. Download the ... Deals and Alliance since 2010 report provides an in-depth ... world,s leading life sciences companies. On demand ... of the most up to date deal and company ...
Breaking Biology News(10 mins):